Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
26. August 2021 12:28 ET
|
Sorrento Therapeutics, Inc.
Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard1 (“LNP-mRNA”) delivered...
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
24. August 2021 10:44 ET
|
Sorrento Therapeutics, Inc.
MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel
23. August 2021 15:52 ET
|
Sorrento Therapeutics, Inc.
Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).Sofusa is a revolutionary technology which delivers biologic...
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives
19. August 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido®...
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
09. August 2021 14:39 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model
04. August 2021 12:57 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), in collaboration with The Scripps Research Institute of La Jolla, today announced that the...
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
20. Juli 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
26. Januar 2021 19:09 ET
|
Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse events noted for any patient treated to date SAN DIEGO, Jan. 26, 2021 ...
Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference
10. Januar 2021 17:58 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference
29. November 2020 20:19 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper...